Search

Displaying results 1831 - 1840 of 10000 in total
  1. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] … [A193671] One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody with the topoisomerase I inhibitor SN-38.

    Categories: Trop-2-Directed Monoclonal AntibodiesProducts: TRODELVY 200 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADET
  2. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout. … It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid.

    Products: OLBETAM CAPSULE 250 mg
  3. Drug

    Factor IX Complex (Human)

    go.drugbank.com/drugs/DB11330
    ApprovedInvestigational

    Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. … As the product Kcentra, Factor IX Complex is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients

    Synonyms: Coagulation factor IX, II, VII and X in combinationProducts: BERIPLEX P/N 500 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, ALPHANINE INJECTION SD 500 IU
  4. Drug

    Etamsylate

    go.drugbank.com/drugs/DB13483
    Investigational

    Products: DICYNONE INJECTION 250 mg/2 ml, QUERCETOL® 250 MG/2 ML SOLUCION INYECTABLE.
  5. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53013] It was granted an Orphan Drug designation by the EMA.[A273833] … [A273833,A273838] Patient cells are then transduced ex vivo with a replication-incompetent retroviral vector (RVV) containing the full-length COL7A1 gene, resulting in cells that express functional collagen

    Synonyms: EB 101, EB-101
  6. Drug

    Enoxacin

    go.drugbank.com/drugs/DB00467
    Approved

    A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

    Categories: Heterocyclic Compounds, 2-Ring, 4-QuinolonesSynonyms: 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid, 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
  7. Drug

    Pipemidic acid

    go.drugbank.com/drugs/DB13823
    Investigational

    Pipemidic acid is a quinolone antibacterial agent with activity against various gram-positive and gram-negative bacteria.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsProducts: ACIDO PIPEMIDICO EG, UROT 400 MG TABLETAS
  8. Drug

    Phenprocoumon

    go.drugbank.com/drugs/DB00946
    ApprovedInvestigationalWithdrawn

    Coumarin derivative that acts as a long-acting oral anticoagulant.

    Categories: Heterocyclic Compounds, 2-Ring, 4-HydroxycoumarinsSynonyms: 4-hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one, 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one
  9. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295]. … In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [A31846].

    Categories: MATE 2 Inhibitors, Cytochrome P-450 SubstratesProducts: ERLEADA ®TABLETAS RECUBIERTAS 60 MG
  10. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL,[ … [L39367] In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersProducts: BRUKINSA 80 mg capsules